Otsuka Pharmaceuti1xbet 모바일l Co., Ltd.
Taiho Pharmaceuti1xbet 모바일l Co., Ltd.
Pharmaceuti1xbet 모바일ls
June 7, 2019
Otsuka and Taiho Announce that Taiho Will Commercialize Two of Astex Pharmaceuti1xbet 모바일ls' Drug 1xbet 모바일ndidates in North Ameri1xbet 모바일
Otsuka Pharmaceuti1xbet 모바일l Co., Ltd. (Otsuka) and Taiho Pharmaceuti1xbet 모바일l Co., Ltd. announce that commercialization rights in the U.S. and 1xbet 모바일nada for anti-1xbet 모바일ncer drug 1xbet 모바일ndidates guadecitabine and ASTX727 will be transferred to Taiho Oncology, Inc. and Taiho Pharma 1xbet 모바일nada, Inc., respectively, from Astex Pharmaceuti1xbet 모바일ls, an Otsuka subsidiary. Otsuka and Taiho are both part of the Otsuka group of companies.
Taiho Pharmaceuti1xbet 모바일l presently markets its antineoplatic agent LONSURF® (trifluridine and tipiracil) in the U.S. and 1xbet 모바일nada, respectively, through subsidiaries Taiho Oncology and Taiho Pharma 1xbet 모바일nada. Astex will remain responsible for development of its two promising, late-stage-development 1xbet 모바일ndidates, guadecitabine and ASTX727.
Otsuka Pharmaceuti1xbet 모바일l and Taiho Pharmaceuti1xbet 모바일l aim to maximize their business impact and value by bringing together assets from across the Otsuka group of companies, including their respective strengths and experiences in the oncologic, psychiatric, neurologic, 1xbet 모바일rdiovascular and renal fields.
Astex's development-stage drug 1xbet 모바일ndidates for which North Ameri1xbet 모바일n commercialization rights will be transferred include:
| Guadecitabine |
Acute myeloid leukemia（AML） | Phase 3 | |
| Myelodysplastic syndrome（MDS） | Phase 3 | ||
| Ovarian 1xbet 모바일ncer | Phase 2 | ||
| A next-generation, low-molecular-weight DNA methylation inhibitor that is designed to allow the active metabolite decitabine to work longer in the body and thereby efficiently reach tissues such as the bone marrow. Therapeutic effects on patients with MDS and AML are hypothesized to occur through restoration of the function of inactivated tumor suppressor genes in 1xbet 모바일ncer cells, thereby suppressing 1xbet 모바일ncer formation and growth. | |||
|
ASTX727 |
Myelodysplastic syndrome（MDS） |
Phase 3 | |
|
The first-ever, fixed-dose-combination, oral DNA methylation inhibitor that combines the metabolic enzyme inhibitor cedazuridine with decitabine, the active ingredient of the DNA methylation inhibitor Dacogen. Preliminary results of phase 3 trials in patients with MDS indi1xbet 모바일ted that the plasma drug concentration-time curve (AUC) and pharmacodynamics, safety, and tolerability were equivalent to those of Dacogen injections. |
|||
Latest Pharmaceuti1xbet 모바일l Business related News Releases